Dream Water fuels Delivra Health’s 8% revenue growth and positive EBITDA across North America

Delivra Health Brands CEO Gord Davey joined Steve Darling from Proactive to discuss the company’s financial and operational results for the fiscal year ended June 30, 2025. Delivra Health’s portfolio — anchored by its flagship brands Dream Water® and LivRelief™ — continues to deliver innovative solutions addressing common health issues such as sleeplessness, chronic pain, and anxiety. Davey shared that Delivra Health reported an 8% increase in net revenue, driven primarily by strong sales growth in the U.S. market, which helped offset a decline in Canadian revenue stemming from lower activity in licensed LivRelief™ Infused products. This was balanced by increased performance from LivRelief™ Non-Infused and Dream Water Canada offerings. The company also reported a 51% gross profit margin and positive adjusted EBITDA for fiscal 2025 — a clear indicator of its improving financial performance and operational efficiency. Growth was led by double-digit sales increases for both Dream Water® USA and Dream Water® Canada across e-commerce and retail channels, reflecting the brand’s rising market presence and the payoff of targeted marketing investments. Looking ahead, Davey said Delivra Health expects to see continued traction with major retail partners, while exploring new international expansion opportunities. With a robust pipeline of innovative products and a focus on scaling its core brands globally, the company is confident it can deliver significant improvements in both revenue and profitability in the year ahead. #proactiveinveestors #delivrahealthbrandsinc #tsxv #dhb #otcqb #dhbuf #DreamWater #GlobalExpansion #UAE #MiddleEastMarket #SleepAid #HealthAndWellness #PharmacyProducts #RegulatoryCompliance #DreamWater #SleepGummies #Wellness #SleepAid #TravelEssentials #CanadianRetail #HealthAndWellness #InsomniaRelief #SleepBetter #DreamWater #ConsumerHealth #GlobalExpansion #GordDavey #HealthAndWellness #LivRelief #EarningsUpdate #MarketingStrategy #SleepAid #PainRelief #Investing #TSXV